Eliem CEO ex­its as neu­ro up­start chops head­count, piv­ots to pre­clin­i­cal pro­gram

For the sec­ond time in a year, Eliem Ther­a­peu­tics is piv­ot­ing to a dif­fer­ent neu­ro drug — but this time it’s be­ing ac­com­pa­nied by dras­tic per­son­nel changes.

CEO Bob Azel­by is leav­ing the biotech along­side COO and CFO Erin Lavelle and gen­er­al coun­sel Jim Buch­er. They are among 55% of the staffers who are be­ing let go as part of a re­or­ga­ni­za­tion around the lead pro­gram.

Eliem had 19 full-time em­ploy­ees and 12 part-time em­ploy­ees as of the end of 2021, ac­cord­ing to its most re­cent dis­clo­sure. Shares $ELYM fell about 10% to $3 in pre-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER